JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
CJC-1295 DAC is a synthetically modified peptide analogue classified within the growth hormone–releasing hormone (GHRH) sequence family from a structural standpoint. In biochemical research contexts, it is referenced as a model compound for examining peptide–receptor interaction architecture and signalling pathway association within controlled laboratory systems. The peptide was originally developed by ConjuChem Technologies in the early 2000s as part of an investigative program focused on peptide modification strategies addressing rapid molecular degradation observed in unmodified GHRH analogues.
CJC-1295 with Drug Affinity Complex (DAC) consists of a 29–amino acid peptide sequence incorporating a chemical modification designed to alter peptide–protein interaction behaviour. This modification involves conjugation that facilitates albumin-adjacent binding characteristics, which are studied in laboratory environments for their impact on peptide stability and degradation kinetics. Comparative analytical studies describe extended persistence parameters relative to unmodified peptide forms under experimental conditions [1]. CJC-1295 with DAC available on our site is supplied strictly for laboratory and research use only, with no clinical, therapeutic, or consumptive application implied.
Molecular Formula: C171H281N49O47Molecular Weight: 3775.4 g/molCAS Number: 863288-34-0
CJC-1295 DAC has been referenced in experimental literature as a synthetically modified peptide analogue associated with growth hormone–releasing hormone (GHRH) sequence research. In laboratory settings, it has been utilised as a molecular probe to examine peptide–receptor interaction frameworks, signalling architecture, and sequence-specific binding behaviour within controlled analytical systems. Certain investigative models have incorporated CJC-1295 as a reference compound in studies focused on pathway mapping and comparative peptide characterisation without attribution to functional or organism-level outcomes [3].
CJC-1295 with Drug Affinity Complex (DAC) is characterised by chemical modification intended to alter peptide persistence and interaction kinetics. Analytical literature describes extended molecular stability parameters and prolonged presence within experimental systems when compared to non-modified peptide forms. These observations are reported strictly within the context of laboratory-based pharmacokinetic modelling and molecular interaction analysis, without implication of physiological relevance or biological effect [1].
Ongoing research on CJC-1295 DAC Available literature for CJC-1295 DAC remains scarce and of exploratory character; current applied studies are also limited to non-clinical and research settings. This compound has not been approved by the U.S. Food and Drug Administration and has no authorized or approved clinical, diagnostic, therapeutic or other uses. Element CRP offers to buy CJC-1295 DAC purely for laboratory, analytical and educational research. Purchase and use are restricted to qualified and licensed research professionals only [4].
CJC-1295 with DAC is a synthetic 30-amino-acid peptide GHRH analogue conjugated to a Drug Affinity Complex (DAC) lysine residue, which promotes serum albumin binding and substantially extends in vitro half-life. The structural modification supports prolonged compound activity across extended cell culture incubation periods relative to native GHRH.
Cell-based research with CJC-1295/DAC focuses on GHRH receptor pharmacology profiling using heterologous expression systems and pituitary somatotroph models. Standard readouts include Gas-coupled cAMP elevation, PKA activation, and CREB phosphorylation, with comparative work against native GHRH and related analogues mapping the affinity profile.
Element CRP supplies this product at 2mg per vial. USA-manufactured via solid-phase peptide synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Reconstitution with bacteriostatic water required. Store lyophilised at -20°C; stable for 24 months.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
